Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2006-11-10

Last Posted Date: 2017-03-01

Lead Sponsor: Pamela L. Kunz

Target Recruit Count: 40

Registration Number: NCT00398320

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer

Interventions: Drug: Bevacizumab
Drug: Docetaxel
Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2006-11-01

Last Posted Date: 2017-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00394433

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Adriamycin and Cytoxan (AC)
Drug: ABI-007
Drug: Taxol
Drug: Bevacizumab
Drug: pegfilgrastim

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 197

Registration Number: NCT00394251

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: ABI-007
Drug: Bevacizumab

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 50

Registration Number: NCT00394082

A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment

Phase 1

Completed

Conditions: Lymphedema
Breast Cancer

First Posted Date: 2006-10-27

Last Posted Date: 2014-09-22

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 11

Registration Number: NCT00393497

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Paclitaxel
Drug: 5-FU
Radiation: Radiation Therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-02-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00392704

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 4 locations

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: nab-paclitaxel
Drug: Bevacizumab
Drug: Trastuzumab

First Posted Date: 2006-10-26

Last Posted Date: 2013-09-20

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 29

Registration Number: NCT00392392

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 3 locations

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5-FU
Procedure: Radiation therapy
Procedure: Surgery

First Posted Date: 2006-10-26

Last Posted Date: 2022-03-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT00393068

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions: Drug: erlotinib
Drug: Bevacizumab
Drug: Sulindac

First Posted Date: 2006-10-26

Last Posted Date: 2017-04-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT00392665

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Cediranib
Drug: 5-fluorouracil ( in FOLFOX)
Drug: Leucovorin (in FOLFOX)
Drug: Oxaliplatin (in FOLFOX)

First Posted Date: 2006-10-05

Last Posted Date: 2017-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 1814

Registration Number: NCT00384176

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy